Navigation Links
DURECT Announces ELADUR® (TRANSDUR®-Bupivacaine) Phase II Study Results in Chronic Low Back Pain
Date:4/11/2011

CUPERTINO, Calif., April 11, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today top-line results from a Phase II clinical trial in chronic low back pain for ELADUR® (TRANSDUR®-Bupivacaine), DURECT's proprietary investigational transdermal bupivacaine pain patch.  This study was conducted by DURECT's collaborator, King Pharmaceuticals, which is now owned by Pfizer (NYSE: PFE).  In this study of 263 patients suffering from chronic low back pain, the primary efficacy endpoint of demonstrating a positive treatment difference for the mean change in pain intensity scores from baseline to the mean of weeks 11 and 12 between ELADUR as compared to placebo was not met.  Complete data analysis is on-going.

(Logo:  http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

ELADUR is an investigational transdermal drug patch intended to deliver bupivacaine for up to 3 days from a single application.  Bupivacaine, the active agent in ELADUR, is a potent, FDA-approved long-acting local anesthetic used in regional anesthesia for local tissue infiltration, nerve block, and epidural and intrathecal anesthesia.  ELADUR demonstrated a positive efficacy trend in a Phase 2a study for post-herpetic neuralgia (PHN); a poster describing this study was presented at the 27th Annual Scientific Meeting of the American Pain Society on May 8, 2008 and is accessible on DURECT's website (http://www.durect.com/wt/durect/page_name/Publications).

"Demonstrating efficacy against placebo in a chronic low back pain trial is challenging for any topical locally-acting product," stated James E. Brown, DVM, President and CEO of DURECT.  "We and Pfizer are continuing to analyze this most recent study and will work
'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DURECT to Present at Cowen and Company Health Care Conference
2. DURECT Corporation Invites You to Join its Fourth Quarter 2010 Earnings Conference Call
3. DURECT Reports Data From European Phase IIb Shoulder Study of POSIDUR™ (SABER™-Bupivacaine) and Amendment of the Nycomed Agreement
4. DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product
5. DURECT to Present at the BIO CEO & Investor Conference
6. DURECT to Present at the Credit Suisse 2010 Healthcare Conference
7. DURECT Corporation Announces Third Quarter 2010 Financial Results
8. DURECT Corporation Invites You to Join Its Second Quarter 2010 Earnings Conference Call
9. DURECT to Present at the BMO Capital Markets Focus on Healthcare Conference
10. DURECT Corporation Secures $50 Million Committed Equity Financing Facility
11. DURECT Reports Data From European Phase IIb Hysterectomy Study of POSIDUR(TM) (SABER(TM)-Bupivacaine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014  Decision Resources Group is launching an extension ... to now include ChinaTrack; the new capabilities track the ... interactive dashboard providing detailed brand-level share tracking and analytics. ... level. Other key capabilities of the new ... addition to end-user surveys of healthcare facilities, ChinaTrack data ...
(Date:7/31/2014)... -- Touro University California,s College of Pharmacy is pleased ... of a $150,000 grant by the Joseph & Vera ... research and classroom space on its campus. ... of health sciences, and will help us apply high-tech ... our students," said Shelley Berkley , CEO and ...
(Date:7/31/2014)... Hovione today announced that its API plant in ... pre-approval inspection by the US Food and Drug Administration (FDA). ... Safety Officer, Ms. Britanny Terhar , lasted 5 days ... concluded on the 25 th . The inspection confirmed the ... Good Manufacturing Practices (GMP) and no Form 483 observations were ...
Breaking Medicine Technology:Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Touro University California Garners Grant From Long Foundation 2Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2
(Date:7/31/2014)... August 01, 2014 The 2013 ... increasing 0.89 points from 75.07 in 2012. The ... tourism-related sectors and integrates them into an overall ... become increasingly more satisfied with Hong Kong over ... consistently excelling in service performance in Hong Kong ...
(Date:7/31/2014)... Ce-Classes.com has announced that they are ... professionals, a Systematic Review of Sexual Satisfaction . ... the International Journal of Clinical and Health Psychology. , ... a need to have accurate information about sexual satisfaction ... possible. The material provides a systematic review of ...
(Date:7/31/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
(Date:7/31/2014)... Weblify has finally been released by marketing and advertising ... The result is a perfected and fine tuned platform ... minutes without knowing any HTML or other programming languages. , ... SEO expert, agrees that this platform allows anyone to create ... web site builders out there, but this is truly unique. ...
(Date:7/31/2014)... Cosmetic Town is a new web ... consumers considering cosmetic treatments. The site features doctors ... is to educate prospective patients on a variety of ... validated referral system that helps patients find cosmetic specialists ... respective fields. , Cosmetic Town started its recruitment ...
Breaking Medicine News(10 mins):Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 2Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 3Health News:The New Doctors’ Directory, Cosmetic Town Does the Research for Consumers of Plastic Surgeries 2
... 60-year-old drug chloroquine eliminated certain malignancies in mice, researchers ... common anti-malaria drug called chloroquine can also prevent the ... a U.S. study finds. , The finding may help ... , Scientists at The Scripps Institute and St. Jude,s ...
... to protect the heart, can lead to halting of ... News) -- Men undergoing hormone therapy for prostate cancer ... a significantly higher risk of dying, new research suggests. ... to elevate liver-function test levels. The end result is ...
... Therapy that stimulates the hand muscles may help treat ... causes muscles spasms in musicians, according to a study ... Neurology, the medical journal of the American Academy of ... practiced particular complicated movements for years. The muscle spasms ...
... Inc. (Nasdaq: GTIV ), the nation,s leading provider ... it is,scheduled to present from 1:30 p.m. to 2:00 ... JPMorgan Healthcare Conference in San Francisco., The event ... audio web cast,which may be accessed by visiting ...
... Medical,Affiliates, Inc. (OTC Bulletin Board: UCIA) reported that revenue ... from $63,672,000 for,the year ended September 30, 2006, an ... September 30, 2007 was $17,885,000 or 9%,greater than the ... increase in revenues is attributed to the opening of ...
... taken more seriously , , WEDNESDAY, Dec. 26 (HealthDay News) ... person,s risk of having a stroke or developing dementia, ... to previous research linking "mini-strokes" to full-fledged strokes, make ... neurology at Johns Hopkins University School of Medicine. , ...
Cached Medicine News:Health News:Malaria Drug Promising Against Cancer 2Health News:Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients 2Health News:Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients 3Health News:Stimulating muscles may improve musician's dystonia 2Health News:Gentiva(R) Health Services to Present January 8 at JPMorgan Healthcare Conference in San Francisco 2Health News:Gentiva(R) Health Services to Present January 8 at JPMorgan Healthcare Conference in San Francisco 3Health News:UCI Medical Affiliates, Inc. Reports Fiscal Year End Results for September 30, 2007 2Health News:UCI Medical Affiliates, Inc. Reports Fiscal Year End Results for September 30, 2007 3Health News:Temporary Amnesia, Confusion Raise Stroke, Dementia Risk 2Health News:Temporary Amnesia, Confusion Raise Stroke, Dementia Risk 3
... to 10 inches/ 25 cm thinner than other benchtop ... X-22 Series is the space-saving multipurpose solution for your ... 46 cm wide • 11 Rotor Library • Achieve ... to Spin 1.5 mL & PCR+ Tubes: 24-place ...
... purpose centrifuges offer high-volume versatility along with ... making them ideal for a wide variety ... Four- or six-place sealed swinging bucket ... rotors offered , Lare capacity (4 x ...
... designed to accommodate over 55 centrifuge tubes, ... heat labile samples. Incorporating the latest technology, ... automatic quick cooling from 22 C to ... maintenance brushless motor, low pitch 62 dBA ...
Inquire...
Medicine Products: